| Name | Components | Example of uses, and other notes |
| 7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use |
7 days of Ara-C (cytarabine) plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) |
Acute myelogenous leukemia, excluding acute promyelocytic leukemia |
| ABVD |
doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine |
Hodgkin's lymphoma |
| AC |
doxorubicin (Adriamycin), cyclophosphamide |
breast cancer |
| BACOD |
bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone |
Non-Hodgkin lymphomas |
| BEACOPP |
bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone |
Hodgkin's lymphoma |
| BEP |
bleomycin, etoposide, platinum agent |
testicular cancer, germ cell tumors |
| CA |
cyclophosphamide, doxorubicin (Adriamycin) (same as AC) |
breast cancer |
| CAF |
cyclophosphamide, doxorubicin (Adriamycin), fluorouracil (5-FU) |
breast cancer |
| CAPOX or XELOX |
capecitabine and oxaliplatin |
colorectal cancer |
| CAV |
cyclophosphamide, doxorubicin (Adriamycin), vincristine |
lung cancer |
| CBV |
cyclophosphamide, BCNU (carmustine), VP-16 (etoposide) |
lymphoma |
| CHOEP |
cyclophosphamide, hydroxydaunorubicin (doxorubicin), etoposide, vincristine (Oncovin), prednisone |
Non-Hodgkin lymphomas |
| CEPP |
cyclophosphamide, etoposide, procarbazine, prednisone |
Non-Hodgkin Lymphomas |
| ChlVPP/EVA |
chlorambucil, vincristine (Oncovin), procarbazine, prednisone, etoposide, vinblastine, doxorubicin (Adriamycin) |
Hodgkin's lymphoma |
| CHOP |
cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), prednisone |
non-Hodgkin lymphoma |
| CHOP-R or R-CHOP |
CHOP + rituximab |
B cell non-Hodgkin lymphoma |
| ClaPD |
clarithromycin, pomalidomide, dexamethasone |
multiple myeloma |
| CMF |
cyclophosphamide, methotrexate, fluorouracil (5-FU) |
breast cancer |
| CMV |
cisplatin, methotrexate, vinblastine |
transitional bladder carcinoma |
| COP or CVP |
cyclophosphamide, Oncovin (vincristine), prednisone |
non-Hodgkin lymphoma in patients with history of cardiovascular disease |
| COPP |
cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone |
Hodgkin's lymphoma |
| CT or TC |
docetaxel (Taxotere), cyclophosphamide |
breast cancer |
| CTD |
cyclophosphamide, thalidomide, dexamethasone |
AL amyloidosis |
| CVAD and Hyper-CVAD |
cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone |
aggressive non-Hodgkin lymphoma, lymphoblastic lymphoma, some forms of leukemia |
| CVE |
carboplatin, vincristine, etoposide |
retinoblastoma |
| CYBORD |
cyclophosphamide, bortezomib, dexamethasone |
multiple myeloma, AL amyloidosis |
| DA or DAC |
daunorubicin x 3 days plus ara-C (cytarabine) x 7 days, a variant of 7+3 regimen |
Acute myeloid leukemia, excluding acute promyelocytic leukemia |
| DAT |
daunorubicin, cytarabine (ara-C), tioguanine |
Acute myeloid leukemia |
| DCEP |
dexamethasone, cyclophosphamide, etoposide, platinum agent |
relapsed or refractory multiple myeloma |
| DHAP |
dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent |
Non-Hodgkin lymphomas |
| DHAP-R or R-DHAP |
dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab |
Non-Hodgkin lymphomas |
| DICE |
dexamethasone, ifosfamide, cisplatin, etoposide (VP-16) |
aggressive relapsed lymphomas, progressive neuroblastoma |
| DT-PACE |
dexamethasone, thalidomide, platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide |
multiple myeloma |
| EC |
epirubicin, cyclophosphamide |
breast cancer |
| ECF (MAGIC) |
epirubicin, cisplatin, fluorouracil (5-FU) |
gastric cancer and cancer of the esophagogastric junction (Siewert classification III) |
| EOX |
epirubicin, oxaliplatin, capecitabine |
esophageal Cancer, gastric Cancer |
| EP |
etoposide, platinum agent |
testicular cancer, germ cell tumors |
| EPOCH |
etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin |
Non-Hodgkin lymphomas |
| EPOCH-R or R-EPOCH |
etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab |
B cell Non-Hodgkin lymphomas |
| ESHAP |
etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent |
Non-Hodgkin lymphoma |
| ESHAP-R or R-ESHAP |
etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab |
Non-Hodgkin lymphoma |
| FAM |
fluorouracil, doxorubicin (Adriamycin), mitomycin |
gastric cancer |
| FAMTX |
fluorouracil, doxorubicin (Adriamycin), methotrexate |
gastric cancer |
| FCM or FMC |
fludarabine, cyclophosphamide, mitoxantrone |
B cell non-Hodgkin lymphoma |
| FCM-R or R-FCM or R-FMC or FMC-R |
fludarabine, cyclophosphamide, mitoxantrone plus rituximab |
B cell non-Hodgkin lymphoma |
| FCR |
fludarabine, cyclophosphamide, rituximab |
B cell non-Hodgkin lymphoma |
| FM |
fludarabine, mitoxantrone |
B cell non-Hodgkin lymphoma |
| FM-R or R-FM or RFM or FMR |
fludarabine, mitoxantrone, and rituximab |
B cell non-Hodgkin lymphoma |
| FEC |
fluorouracil (5-FU), epirubicin, cyclophosphamide |
breast cancer |
| FEC-T |
fluorouracil (5-FU), epirubicin, cyclophosphamide together, followed by docetaxel (Taxotere) |
breast cancer |
| FL (also known as Mayo) |
fluorouracil (5-FU), leucovorin (folinic acid) |
colorectal cancer |
| FLAG |
fludarabine, cytarabine, G-CSF |
relapsed or refractory acute myelogenous leukemia |
| FLAG-Ida or FLAG-IDA or IDA-FLAG or Ida-FLAG |
fludarabine, cytarabine, idarubicin, G-CSF |
relapsed or refractory acute myelogenous leukemia |
| FLAG-Mito or FLAG-MITO or Mito-FLAG or MITO-FLAG or FLANG[citation needed] |
mitoxantrone, fludarabine, cytarabine, G-CSF |
relapsed or refractory acute myelogenous leukemia |
| FLAMSA |
fludarabine, cytarabine, amsacrine |
myelodysplastic syndrome, acute myeloid leukemia |
| FLAMSA-BU or FLAMSA-Bu |
fludarabine, cytarabine, amsacrine, busulfan |
myelodysplastic syndrome, acute myeloid leukemia |
| FLAMSA-MEL or FLAMSA-Mel |
fludarabine, cytarabine, amsacrine, melphalan |
myelodysplastic syndrome, acute myeloid leukemia |
| FLOT |
fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, docetaxel |
esophageal cancer, gastric cancer |
| FOLFIRI |
fluorouracil (5-FU), leucovorin (folinic acid), irinotecan |
colorectal cancer |
| FOLFIRINOX |
fluorouracil (5-FU), leucovorin (folinic acid), irinotecan, oxaliplatin |
pancreatic cancer |
| FOLFOX |
fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin |
colorectal cancer |
| GC |
gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin |
bladder cancer |
| GDP |
gemcitabine, dexamethasone, cisplatin |
Non-Hodgkin lymphomas and Hodgkin lymphoma |
| GemOx or GEMOX |
gemcitabine, oxaliplatin |
Non-Hodgkin lymphomas |
| GVD |
gemcitabine, vinorelbine, pegylated liposomal doxorubicin |
Hodgkin lymphoma |
| GemOx-R or GEMOX-R or R-GemOx or R-GEMOX |
gemcitabine, oxaliplatin, rituximab |
Non-Hodgkin lymphomas |
| IA or IAC |
idarubicin x 3 days plus Ara-C (cytarabine) x 7 days, a variant of classical 7+3 regimen |
Acute myelogenous leukemia, excluding acute promyelocytic leukemia |
| ICE |
ifosfamide, carboplatin, etoposide (VP-16) |
aggressive lymphomas, progressive neuroblastoma |
| ICE-R or R-ICE or RICE |
ICE + rituximab |
high-risk progressive or recurrent lymphomas |
| IFL |
irinotecan, leucovorin (folinic acid), fluorouracil |
colorectal cancer |
| IVA |
ifosfamide, vincristine, actinomycin D |
rhabdomyosarcoma |
| MAP or MAPIE |
Doxorubicin (Adriamycin), Cisplatin, Methotrexate, Ifosfamide (Ifex), Etoposide (Vepesid) |
Bone cancer, Osteosarcoma |
| m-BACOD |
methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone |
non-Hodgkin lymphoma |
| MACOP-B |
methotrexate, leucovorin (folinic acid), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin |
non-Hodgkin lymphoma |
| MAID |
mesna, doxorubicin, ifosfamide, dacarbazine |
soft-tissue sarcoma |
| MINE |
mesna, ifosfamide, novantrone, etoposide |
Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases |
| MINE-R or R-MINE |
mesna, ifosfamide, novantrone, etoposide plus rituximab |
Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases |
| MMM |
mitomycin, methotrexate, mitoxantrone |
breast cancer |
| MOPP |
mechlorethamine, vincristine (Oncovin), procarbazine, prednisone |
Hodgkin's lymphoma |
| MVAC |
methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin |
advanced bladder cancer[4] |
| MVP |
mitomycin, vindesine, cisplatin |
lung cancer and mesothelioma |
| NP |
cisplatin, vinorelbine |
non-small cell lung carcinoma |
| PACE |
platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide |
|
| PCV |
Procarbazine, CCNU (lomustine), vincristine |
brain tumors |
| PEB |
cisplatin, etoposide, bleomycin |
non-seminomatous germ cell tumors |
| PEI |
cisplatin, etoposide, ifosfamide |
small-cell lung carcinoma |
| platin + taxane[5] |
cisplatin/carboplatin, paclitaxel/docetaxel |
ovarian cancer |
| POMP |
6-mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone |
acute adult leukemia[6] |
| ProMACE-MOPP |
methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP |
non-Hodgkin lymphoma |
| ProMACE-CytaBOM |
prednisone, doxorubicin (Adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin |
non-Hodgkin lymphoma |
| RdC |
lenalidomide (Revlimid), dexamethasone, cyclophosphamide |
AL amyloidosis |
| R-Benda |
rituximab + bendamustine |
follicular lymphoma and MALT lymphoma[7] |
| R-DHAP or DHAP-R |
rituximab + DHAP; that is, rituximab, dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent |
relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma |
| R-FCM or FCM-R |
rituximab + FCM; that is, rituximab, fludarabine, cyclophosphamide, mitoxantrone |
B cell non-Hodgkin lymphoma |
| R-ICE or ICE-R or RICE |
rituximab + ICE; that is, rituximab, ifosfamide, carboplatin, etoposide |
high-risk progressive or recurrent lymphomas |
| RVD |
lenalidomide (Revlimid), bortezomib, dexamethasone |
|
| Stanford V |
doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone |
Hodgkin lymphoma |
| TAC or ACT |
docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide |
breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) |
| TAD |
tioguanine, cytarabine (ara-C), daunorubicin |
acute myeloid leukemia |
| TC or CT |
docetaxel (Taxotere), cyclophosphamide |
breast cancer |
| TCH |
docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) |
breast cancer with positive HER2/neu receptor |
| TCHP |
docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) |
breast cancer with positive HER2/neu receptor |
| Thal/Dex |
thalidomide, dexamethasone |
multiple myeloma |
| TIP |
paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol) |
testicular cancer, germ cell tumors in salvage therapy |
| EE-4A |
vincristine, actinomycin[8] |
Wilms' tumor[8] |
| DD-4A |
vincristine, actinomycin, doxorubicin (Adriamycin)[8] |
Wilms' tumor[8] |
| VABCD |
vinblastine, doxorubicin (Adriamycin), bleomycin, lomustine (CeeNU), dacarbazine |
MOPP refractory Hodgkin's Lymphoma |
| VAC |
vincristine, actinomycin, cyclophosphamide |
rhabdomyosarcoma |
| VAD |
vincristine, doxorubicin (Adriamycin), dexamethasone |
multiple myeloma |
| VAMP |
one of 3 combinations of vincristine and others |
Hodgkin's lymphoma, leukemia, multiple myeloma |
| Regimen I |
vincristine, doxorubicin (Adriamycin), etoposide, cyclophosphamide |
Wilms' tumor[8] |
| VAPEC-B |
vincristine, doxorubicin (Adriamycin), prednisone, etoposide, cyclophosphamide, bleomycin |
Hodgkin's lymphoma |
| VDC-IE |
vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide |
Ewing's sarcoma |
| VD-PACE |
bortezomib, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide |
multiple myeloma |
| VIFUP |
vinorelbine, cisplatin, fluorouracil |
locally advanced/metastatic breast cancer |
| VIP |
vinblastine, ifosfamide, platinum agent, (etoposide (VP-16) may substitute for vinblastine, making a regimen sometimes referred to as VIP-16)[9][10] |
testicular cancer, germ cell tumors |
| VTD-PACE |
bortezomib (Velcade), thalidomide, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide |
multiple myeloma |
| V-DCEP |
bortezomib (Velcade), dexamethasone, cyclophosphamide, etoposide, platinum agent |
relapsed or refractory multiple myeloma |